3 Highly Rated Biotech Stocks for Your July Buy List
The healthcare sector continues to be a hotbed of innovation, with biotechnology leading the charge. From groundbreaking gene therapies to next-generation cancer treatments, biotech companies are p...
Levi & Korsinsky Reminds Biogen Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB
NEW YORK, NY / ACCESSWIRE / July 4, 2024 / If you suffered a loss on your Biogen Inc. (NASDAQ:BIIB) investment and want to learn about a potential recovery under the federal securities laws, follow...
BIIB SHAREHOLDER ALERT: Kessler Topaz Meltzer & Check, LLP Reminds Biogen Inc. (BIIB) Investors of Securities Fraud Class Action Lawsuit Filed On t...
RADNOR, Pa. , July 4, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United St...
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Biogen To Contact Him Directly To Discuss Their Options If you ...
Lilly follows Biogen-Eisai in securing US FDA approval for Alzheimer's drug
Eli Lilly's Kisunla secured standard approval from the U.S. Food and Drug Administration on Tuesday for slowing the progression of Alzheimer's disease.
Biogen Inc. Class Action: Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, ...
NEW YORK, NY / ACCESSWIRE / July 2, 2024 / If you suffered a loss on your Biogen Inc. (NASDAQ:BIIB) investment and want to learn about a potential recovery under the federal securities laws, follow...
Biogen Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information - BIIB
NEW YORK, NY / ACCESSWIRE / July 2, 2024 / If you suffered a loss on your Biogen Inc. (NASDAQ:BIIB) investment and want to learn about a potential recovery under the federal securities laws, follow...
The Schall Law Firm Encourages Biogen Inc Investors Who Have Sustained Losses To Make Contact Be Mindful Of The Deadline In This Situation
LOS ANGELES, CA / ACCESSWIRE / July 2, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Biogen Inc. ("Biogen" or "the ...
Eli Lilly Snags Long-Awaited Alzheimer's Drug Approval, Rivaling Biogen, Eisai
Eli Lilly won FDA approval for its Alzheimer's treatment, donanemab, on Tuesday. But Eli Lilly stock remained in the red.
Biogen Completes Acquisition of Human Immunology Biosciences
CAMBRIDGE, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Human Immunology Biosciences (HI-Bio™), a privately-held clinical-stage biotechnology...
Investors in Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights – BIIB
NEW YORK, NY / ACCESSWIRE / July 1, 2024 / If you suffered a loss on your Biogen Inc. (NASDAQ:BIIB) investment and want to learn about a potential recovery under the federal securities laws, follow...
UPCOMING BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit!
NEW YORK, NY / ACCESSWIRE / July 1, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Biogen Inc. ("...
Biogen Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB
NEW YORK, NY / ACCESSWIRE / June 30, 2024 / If you suffered a loss on your Biogen Inc. (NASDAQ:BIIB) investment and want to learn about a potential recovery under the federal securities laws, follo...
Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Class Action Lawsuit Against Biogen Inc. (BIIB)
RADNOR, Pa. , June 28, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United ...
“LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer's Disease Launched in China
China is the Third Country to Launch LEQEMBI Following the United States and Japan China is the Third Country to Launch LEQEMBI Following the United States and Japan
Related Companies